A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Harrow Health, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 293,770 shares of HROW stock, worth $14.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
293,770
Previous 306,208 4.06%
Holding current value
$14.7 Million
Previous $6.4 Million 106.49%
% of portfolio
0.02%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$20.85 - $46.47 $259,332 - $577,993
-12,438 Reduced 4.06%
293,770 $13.2 Million
Q2 2024

Aug 09, 2024

SELL
$10.0 - $21.64 $1.71 Million - $3.7 Million
-171,150 Reduced 35.85%
306,208 $6.4 Million
Q1 2024

May 13, 2024

SELL
$9.3 - $13.23 $1.24 Million - $1.77 Million
-133,822 Reduced 21.9%
477,358 $6.32 Million
Q4 2023

Feb 13, 2024

SELL
$8.1 - $16.36 $2.75 Million - $5.56 Million
-339,878 Reduced 35.74%
611,180 $6.85 Million
Q3 2023

Nov 14, 2023

BUY
$14.03 - $22.08 $838,236 - $1.32 Million
59,746 Added 6.7%
951,058 $13.7 Million
Q2 2023

Aug 11, 2023

SELL
$17.37 - $28.08 $1.24 Million - $2 Million
-71,300 Reduced 7.41%
891,312 $17 Million
Q1 2023

May 12, 2023

SELL
$13.84 - $21.46 $2.34 Million - $3.63 Million
-169,375 Reduced 14.96%
962,612 $20.4 Million
Q4 2022

Feb 13, 2023

BUY
$10.28 - $14.78 $199,175 - $286,362
19,375 Added 1.74%
1,131,987 $16.7 Million
Q3 2022

Nov 14, 2022

SELL
$6.57 - $24.88 $362,664 - $1.37 Million
-55,200 Reduced 4.73%
1,112,612 $13.4 Million
Q2 2022

Aug 12, 2022

BUY
$5.75 - $7.74 $453,692 - $610,709
78,903 Added 7.25%
1,167,812 $8.5 Million
Q1 2022

May 13, 2022

SELL
$6.77 - $8.66 $746,074 - $954,357
-110,203 Reduced 9.19%
1,088,909 $7.43 Million
Q4 2021

Feb 11, 2022

SELL
$8.5 - $12.0 $586,500 - $828,000
-69,000 Reduced 5.44%
1,199,112 $10.4 Million
Q3 2021

Nov 12, 2021

SELL
$6.99 - $10.6 $918,486 - $1.39 Million
-131,400 Reduced 9.39%
1,268,112 $11.5 Million
Q2 2021

Aug 13, 2021

SELL
$6.68 - $11.07 $1.1 Million - $1.82 Million
-164,700 Reduced 10.53%
1,399,512 $13 Million
Q1 2021

May 13, 2021

BUY
$6.26 - $11.03 $444,460 - $783,130
71,000 Added 4.75%
1,564,212 $10.6 Million
Q4 2020

Feb 10, 2021

BUY
$4.76 - $6.93 $760,329 - $1.11 Million
159,733 Added 11.98%
1,493,212 $10.2 Million
Q3 2020

Nov 13, 2020

BUY
$4.71 - $7.36 $88,548 - $138,368
18,800 Added 1.43%
1,333,479 $7.45 Million
Q2 2020

Aug 13, 2020

BUY
$3.61 - $6.47 $8,927 - $16,000
2,473 Added 0.19%
1,314,679 $6.85 Million
Q1 2020

May 14, 2020

BUY
$3.5 - $7.31 $266,000 - $555,560
76,000 Added 6.15%
1,312,206 $5.01 Million
Q4 2019

Feb 13, 2020

SELL
$4.6 - $7.88 $75,900 - $130,020
-16,500 Reduced 1.32%
1,236,206 $9.62 Million
Q3 2019

Nov 13, 2019

BUY
$4.89 - $8.0 $519,317 - $849,600
106,200 Added 9.26%
1,252,706 $7.04 Million
Q2 2019

Aug 12, 2019

BUY
$4.2 - $8.7 $750,540 - $1.55 Million
178,700 Added 18.46%
1,146,506 $9.98 Million
Q1 2019

May 14, 2019

BUY
$4.75 - $7.1 $4.6 Million - $6.87 Million
967,806 New
967,806 $4.82 Million

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.35B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.